In the 2022 version of the Chinese Society of Clinical Oncology breast cancer guideline and The National Comprehensive Cancer Network guideline, anthracycline/cyclophosphamide followed by taxane/trastuzumab [AC-TH] is the recommended neoadjuvant therapy with obvious curative effect for HER2-positive breast cancer patients [5, 6]. This evidence concerns the gene ERBB2 and breast carcinoma.